Keywords: Protalix, Elelyso, Gaucher disease, Israel, Pfizer
Protalix gains Israeli approval for Gaucher drug Elelyso
Article | 01 October 2012
Israel-based Protalix BioTherapeutics (NYSE-AMEX: OLX) has received marketing authorization from the Israeli Ministry of Health for Elelyso (taliglucerase alfa) for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
